Health Care & Life Sciences » Biotechnology | Mesoblast Ltd.

Mesoblast Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
16,410.00
20,483.00
56,986.90
2,577.70
21,907.80
Cost of Goods Sold (COGS) incl. D&A
27,754.00
29,206.00
40,900.40
15,998.10
7,108.60
Gross Income
11,344.00
8,723.00
16,086.40
13,420.40
14,799.20
SG&A Expense
80,767.00
113,765.00
99,647.60
108,626.60
113,357.60
EBIT
92,111.00
122,488.00
83,561.20
122,047.00
98,558.40
Unusual Expense
5,551.00
18,422.00
46,457.70
172.40
13,604.10
Non Operating Income/Expense
1,456.00
12,968.00
1,547.40
57.00
638.80
Interest Expense
-
-
-
-
2,360.50
Pretax Income
89,548.00
124,677.00
130,083.50
121,655.80
87,481.30
Income Tax
8,590.00
5,309.00
124,412.20
19,799.70
41,936.40
Consolidated Net Income
80,958.00
119,368.00
5,671.30
101,856.10
45,544.90
Net Income
80,958.00
119,368.00
5,671.30
101,856.10
45,544.90
Net Income After Extraordinaries
80,958.00
119,368.00
5,671.30
101,856.10
45,544.90
Net Income Available to Common
80,958.00
119,368.00
5,671.30
101,856.10
45,544.90
EPS (Basic)
0.25
0.37
0.02
0.26
0.10
Basic Shares Outstanding
322,688.20
324,119.50
364,456.70
399,314.10
465,689.00
EPS (Diluted)
0.25
0.37
0.02
0.26
0.10
Diluted Shares Outstanding
322,688.20
324,119.50
364,456.70
399,314.10
465,689.00
EBITDA
90,991.00
120,533.00
80,549.00
117,993.40
95,138.40
Non-Operating Interest Income
9,570.00
3,265.00
1,482.80
620.60
472.40

About Mesoblast

View Profile
Address
55 Collins Street
Melbourne Victoria (VIC) 3000
Australia
Employees -
Website http://www.mesoblast.com
Updated 07/08/2019
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.